Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$121.66
-0.49 (-0.40%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$121.10
$124.00
50-Day Range
$100.57
$124.11
52-Week Range
$71.88
$125.99
Volume
496,611 shs
Average Volume
792,320 shs
Market Capitalization
$11.70 billion
P/E Ratio
213.44
Dividend Yield
N/A
Price Target
$124.00

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.59 Rating Score
Upside/​Downside
1.9% Upside
$124.00 Price Target
Short Interest
Healthy
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
1.10mentions of Neurocrine Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8.40 M Sold Last Quarter
Proj. Earnings Growth
97.41%
From $1.93 to $3.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

283rd out of 1,040 stocks

Biological Products, Except Diagnostic Industry

40th out of 175 stocks

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Could Pfizer Stock Help You Retire a Millionaire?
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
We're Adjusting Our Strategy for Neurocrine Biosciences
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
11/01/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/10/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$124.00
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$94.00
Forecasted Upside/Downside
+1.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.59
Research Coverage
17 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.24 per share
Book Value
$14.48 per share

Miscellaneous

Free Float
91,904,000
Market Cap
$11.70 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 64)
    CEO & Director
    Comp: $1.58M
  • Mr. Matthew C. AbernethyMr. Matthew C. Abernethy (Age 42)
    Chief Financial Officer
    Comp: $906.76k
  • Dr. Jude Onyia Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $621.66k
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 57)
    Chief Commercial Officer
    Comp: $805k
  • Dr. Eiry Wyn Roberts M.D. (Age 58)
    Chief Medical Officer
    Comp: $925.46k
  • Dr. Dimitri E. GrigoriadisDr. Dimitri E. Grigoriadis (Age 64)
    Chief Research Officer
  • Jane Sorensen
    Head of Investor Relations
  • Mr. Darin M. LippoldtMr. Darin M. Lippoldt (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Kyle W. GanoMr. Kyle W. Gano (Age 49)
    Chief Bus. Devel. and Strategy Officer
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 56)
    Chief HR Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

17 Wall Street research analysts have issued 12-month price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $154.00. On average, they predict the company's stock price to reach $124.00 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2022?

Neurocrine Biosciences' stock was trading at $85.17 at the start of the year. Since then, NBIX shares have increased by 42.8% and is now trading at $121.66.
View the best growth stocks for 2022 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its earnings results on Monday, November, 1st. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.28. The company had revenue of $296 million for the quarter, compared to analyst estimates of $297.02 million. Neurocrine Biosciences had a net margin of 4.19% and a trailing twelve-month return on equity of 4.06%. Neurocrine Biosciences's revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.62) earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.53%), Vanguard Group Inc. (9.36%), State Street Corp (3.92%), Bellevue Group AG (2.97%), Bank of New York Mellon Corp (1.81%) and Price T Rowe Associates Inc. MD (1.52%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $121.66.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $11.70 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 11/28/2022 by MarketBeat.com Staff